Senseonics Begins European Rollout of Eversense 365; Early Launch in Sweden

What happened

Senseonics has announced the European launch of Eversense 365, the world's first one-year CGM, starting in Sweden with a phased rollout to Germany, Spain, and Italy in the coming weeks. This milestone follows CE Mark submission and supports the bull case for geographic diversification, but initial volumes are expected to be modest relative to the company's cash burn. The launch occurs as Senseonics undertakes a risky transition to insourced U.S. commercialization, which will test its ability to sustain revenue growth and achieve the targeted ~50% gross margins in 2026. While the European expansion adds a potential revenue stream, it does not alleviate the near-term balance sheet pressure or the need for additional capital, as flagged in our report. Investors should monitor European adoption and reimbursement, but the core thesis remains centered on U.S. commercial execution and funding clarity.

Implication

The European launch validates the product's differentiated value and adds a potential revenue stream, but initial sales are unlikely to move the needle given the company's ~$60M annual cash burn. The stock already prices in aggressive growth; until we see evidence that insourced U.S. commercialization can deliver $60M+ revenue and ~50% gross margins, the risk of dilution or shortfall remains high around $7. An attractive entry remains closer to $4.50, where the downside is better protected.

Thesis delta

The news confirms the product's global potential, which was already part of our base and bull scenarios. The core thesis remains unchanged: wait for proof that the insourced commercial model can deliver on 2026 guidance and that funding is secure. The EU launch is a positive data point but does not warrant upgrading from WAIT.